|
GB0300597D0
|
|
Phage biofilms
|
|
US2003215469A1
|
|
Multicomponent meningococcal vaccine
|
|
WO03008631A2
|
|
Tagging of microorganisms
|
|
GB0216865D0
|
|
Targetted agents for nerve regeneration
|
|
GB0216146D0
|
|
Degradation and detection of TSE infectivity
|
|
GB0216098D0
|
|
Treatment of TSE infection
|
|
GB0207602D0
|
|
OMV production and modified bacteria therefor
|
|
GB0207605D0
|
|
Tagging of microorganisms
|
|
GB0126266D0
|
|
Anthrax antigenic compositions
|
|
GB0125535D0
|
|
Mycobacterial genes down-regulated during latency
|
|
GB0125077D0
|
|
Control of sporulation of clostridia and pharmaceutical uses thereof
|
|
AU8143001A
|
|
Method of making microencapsulated DNA for vaccination and gene therapy
|
|
GB0124593D0
|
|
Mycobacterial antigens expressed under high oxygen tension
|
|
GB0123993D0
|
|
Mycobacterial antigens expressed during latency
|
|
GB0121780D0
|
|
Mycobacterial antigens expressed under low oxygen tension
|
|
GB0120328D0
|
|
Control of sporulation of clostridia
|
|
US6406719B1
|
|
Encapsulation of bioactive agents
|
|
GB0117787D0
|
|
Tagging of microorganisms
|
|
GB0116385D0
|
|
Mycobacterial antigens expressed during latency
|
|
GB0115365D0
|
|
Mycobacterial antigens expressed under low oxygen tension
|
